Since joining Vertex Pharmaceuticals in 2015, David Altshuler, MD, PhD, has been instrumental in bringing several new medicines to patients living with serious genetic diseases, most notably cystic fibrosis (CF), including ORKAMBI®, SYMDEKO® and TRIKAFTA . . .
The post From Genomes to Drugs: An Interview with Vertex CSO David Altshuler appeared first on GEN – Genetic Engineering and Biotechnology News.
